Wockhardt Limited

rs,

forward-looking statement in this presentation, whether as a result of changes in underlying factors, new information, future events or otherwise. The information in this document have been collected wi

INR 3,033

er purpose without specific written and prior approval 2 Global Research - driven multinational INR 3,033 Cr. FY25 Income INR 418 Cr. FY25 EBITDA Novel Antibiotics Biotechnology Pharmaceuticals 3 G

INR 418

ritten and prior approval 2 Global Research - driven multinational INR 3,033 Cr. FY25 Income INR 418 Cr. FY25 EBITDA Novel Antibiotics Biotechnology Pharmaceuticals 3 Global Footprint FY25 sales

39%

ss globe 2 R&D centers one each in India, UK UK India Emerging Markets Ireland (& other EU) 39% 23% 23% 12% 4 Stronger business performance 67% Y-o-Y EBITDA growth1 0.01 Net Debt : Equity

23%

obe 2 R&D centers one each in India, UK UK India Emerging Markets Ireland (& other EU) 39% 23% 23% 12% 4 Stronger business performance 67% Y-o-Y EBITDA growth1 0.01 Net Debt : Equity ratio

12%

centers one each in India, UK UK India Emerging Markets Ireland (& other EU) 39% 23% 23% 12% 4 Stronger business performance 67% Y-o-Y EBITDA growth1 0.01 Net Debt : Equity ratio2 20% gro

67%

dia Emerging Markets Ireland (& other EU) 39% 23% 23% 12% 4 Stronger business performance 67% Y-o-Y EBITDA growth1 0.01 Net Debt : Equity ratio2 20% growth for biosimilars in emerging markets

20%

3% 12% 4 Stronger business performance 67% Y-o-Y EBITDA growth1 0.01 Net Debt : Equity ratio2 20% growth for biosimilars in emerging markets3 INR 326 Cr. Reduction in debt4 1. 2. 3. 4. Growth in

INR 326

o-Y EBITDA growth1 0.01 Net Debt : Equity ratio2 20% growth for biosimilars in emerging markets3 INR 326 Cr. Reduction in debt4 1. 2. 3. 4. Growth in FY25 over FY24 As on 31st March 2025, excluding prom

INR 64

h 2025, excluding promoter debt & net of cash & cash equivalents and other bank balances (Net Debt: INR 64 Cr ; Equity: INR 4,657 Cr.) Growth in FY25 over FY24 As at 31st March 2025 vs 31st March 2024 (exclu

INR 4,657

omoter debt & net of cash & cash equivalents and other bank balances (Net Debt: INR 64 Cr ; Equity: INR 4,657 Cr.) Growth in FY25 over FY24 As at 31st March 2025 vs 31st March 2024 (excluding promoter debt) 5

90%

obal Phase III cUTI study with 20% superiority  Phase II Carbapenem-Resistant Organism study with >90% clinical efficacy  NDA filed with DCGI, India  Compassionate use: 51 lives saved MIQNAF® (Nafith

Pathogen coverage includes

1

Pathogen coverage includes

Carbapenem resistant Acinetobacter B (CRAB), Carbapenem resistant Enterobacterales (CRE), Carbapenem resistant Pseudomonas A (CRPA) & Carbapenem resistant Stenotrophomonas including MBL producers ~371K carbapenem resistant cases in US & Europe ~4.3 million hospitalized cases for key gram-negative pathogens New class antibiotic WCK 5222 offers addressable market opportunity of ~US$ 7 billion in USA & Europe 20 MIQNAF® (Nafithromycin) Next generation respiratory tract infection antibiotic Wockhardt has ended a wait of > 30 years for a new antibiotic in Macrolide class with approval and launch of Miqnaf® (Nafithromycin) 22 MIQNAF® (Nafithromycin): Broad spectrum novel lactone ketolide for Community Acquired Bacterial Pneumonia (CABP) & Upper Respiratory tract infections(RTI) Increasing resistance and incomplete coverage for current treatment options: − Macrolides (Azithromycin, Erythromycin) resistance in S. Pneumonia of ~65% in India − Lack of atypical pathogen coverage by Amoxicillin/Cl